The FDA granted a new indication to cabozantinib (Cabometyx, Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Nexavar, Bayer).
The FDA’s latest approval of cabozantinib was based on results from the CELESTIAL phase 3 pivotal trial of cabozantinib for patients with advanced HCC who received prior sorafenib. The randomized, double blind, placebo-controlled trial was conducted at more than 100 locations in 19 countries, and enrolled